prednisone has been researched along with gdc-0068 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, P; Gallo, JD; Hinton, H; Huang, KC; Miles, DR; Rasuo, G; Rotmensch, J; Sane, RS; Sutaria, DS | 1 |
| Bracarda, S; Chen, G; Chi, KN; de Bono, J; Garcia, J; Harris, A; Hinton, H; Massard, C; Matsubara, N; Olmos, D; Sandhu, S; Sane, R; Schenkel, F; Sternberg, CN; Sweeney, C | 1 |
2 trial(s) available for prednisone and gdc-0068
| Article | Year |
|---|---|
Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Blood Glucose Self-Monitoring; Glucose; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Humans; Hyperglycemia; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |